How this could turn into the greatest Venture bull market ever…
Learn more in today’s Week In Review And A Look Ahead!
BMR subscribers have enjoyed market-trouncing returns through our boots-on-the-ground research and unbeatable technical and fundamental analysis of speculative niche sectors, with Sona Nanotech (SONA, CSE) being the latest example.
If you’re a non-BMR subscriber at the moment, and would like a free eAlert highlighting one of our top opportunities, email us at: [email protected] (must include first name).
To read the rest of today’s Week In Review And A Look Ahead!, sign up NOW or login as a current subscriber with your username and password.
Questions for us? Email us at: [email protected].
Regarding SONA,in your opinion, what do you think will come first, the FDA or getting listed on the Nasdaq?
Thank you
Comment by Labrador — July 12, 2020 @ 7:47 am
Hi Jon,
My company’s 401(k) plan does not allow common stock or ETF. Can you recommend a few mutual funds that are gold, silver, and/or Swiss Franc oriented? The destruction of the USD begins this fall.
Thanks for any input,
Marshall
Comment by Marshall — July 12, 2020 @ 7:56 am
For sure, Marshall.
Comment by Jon - BMR — July 12, 2020 @ 7:59 am
FDA approval will come first, Labrador, and fairly quickly IMHO…
Comment by Jon - BMR — July 12, 2020 @ 8:00 am
Do you anticipate any healthy pullback on SONA occurring in the meantime until FDA approval (ie. to the 7.41 or 6 support areas?) or do technicals not matter at this point in this unfolding story? RSI daily and weekly seem high but will FDA news happen first and then all heck will break lose?!
Comment by toro — July 12, 2020 @ 9:07 am
The Fib. level around $7.40 held nicely last week, toro, and there’s no reason to believe it won’t continue to hold. To the upside, nearest measured Fib. is just above $11. Don’t count on a “healthy” pullback below nearest Fib. At any point this could also get some interesting attention from media + influencers in the U.S. and elsewhere. Be very careful not to get traded out of your position ahead of FDA approval, likely during this 2nd half of July as suggested in SONA’s validation NR.
Comment by Jon - BMR — July 12, 2020 @ 9:41 am
Sounds good! Thank you for your quick reply.
Comment by toro — July 12, 2020 @ 9:45 am
Well I waited for a pull back to below 7 .. got it for 2 minutes, but missed it by 5 minutes… so currently out.. It HAS to come down to some level.. the CMF is weak.. and it is SO far above the averages… it HAS to until it doesnt:)
Toro .. you have company here:) hopefully we have that 2nd chance to re-enter!!
Comment by Jeremy — July 12, 2020 @ 10:45 am
I still have a core position but considering to add again. I thought normally this should pull back but this is such a compelling and developing story and they are marching on steadily.
I’m also not sure about what happens when the virus mutates too much with antigen drift/shift and how easy it is to modify the test to account for any antigen drifts /shifts. I’m sure Darren and team will figure it out!
Comment by toro — July 12, 2020 @ 1:12 pm
The key to handling the mutation of the virus, toro, is having the right mix of biologics – on that point, SONA has things very well covered. They’ve been constantly thinking ahead.
Comment by Jon - BMR — July 12, 2020 @ 1:23 pm
That’s great to hear! They have certainly done well so far and progressing smoothly.
Looking forward to this month and rest of the year.
Comment by toro — July 12, 2020 @ 2:00 pm